In a multicenter Phase I/II trial, divarasib demonstrated a confirmed overall response rate (ORR) of 53% in KRAS G12C-mutant NSCLC and 29% in colorectal cancer (CRC), with median progression-free survival (PFS) of 13.1 months (NSCLC) and 5.6 months (CRC). This evidence concerns the gene KRAS and colorectal carcinoma.